Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent protecte
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.